A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation
About the study
The purpose of this study is to evaluate if milvexian is at least as effective as apixaban for reducing the risk of the composite stroke and non-central nervous system (CNS) systemic embolism.
Who can take part
You may be eligible to participate in the study if you meet the following criteria:
INCLUSION CRITERIA
Inclusion Criteria:
- Minimum age of 18 years
- Medically stable and appropriate for chronic antithrombotic treatment
- Atrial fibrillation eligible to receive anticoagulation
- Participant must satisfy one or both of the following categories of risk factors (a or b): a) one or more of the following risk factors: i) age greater than or equal to 75 years, ii) history of any type of stroke including symptomatic stroke of any kind. b) two or more of the following risk factors: i) age between 65 and 74 years, ii) hypertension, iii) diabetes mellitus, iv) atherosclerotic vascular disease, v) heart failure
EXCLUSION CRITERIA
Exclusion Criteria:
- Hemodynamically significant valve disease or those with valve disease that will potentially require surgical valve replacement during the study
- Any condition other than AF that requires chronic anticoagulation
Study Locations
Enter your ZIP code/Postal code/PIN code to locate study sites near you:
How to Apply
Contact the study center to learn if this study is a good match for you.
Study Details
Contition
Atrial Fibrillation
Age
18+
Phase
PHASE3
Participants Needed
15500
Est. Completion Date
May 5, 2027
Treatment Type
INTERVENTIONAL
Sponsor
Janssen Research & Development, LLC
ClinicalTrials.gov NCT Identifier
NCT05757869
Study Number
70033093AFL3002
Understanding Clinical Trials
Get answers to your questions about clinical trials.What is clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?